Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 9.9 USD -5.62%
Market Cap: $535.8m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
535.7m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
571.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
286B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
299.8B USD
Loading...
CH
Novartis AG
SIX:NOVN
226.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
213.9B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
154.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Fulcrum Therapeutics Inc
Glance View

Market Cap
535.8m USD
Industry
Pharmaceuticals

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

FULC Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top